PE20040066A1 - NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na - Google Patents

NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na

Info

Publication number
PE20040066A1
PE20040066A1 PE2003000511A PE2003000511A PE20040066A1 PE 20040066 A1 PE20040066 A1 PE 20040066A1 PE 2003000511 A PE2003000511 A PE 2003000511A PE 2003000511 A PE2003000511 A PE 2003000511A PE 20040066 A1 PE20040066 A1 PE 20040066A1
Authority
PE
Peru
Prior art keywords
blocker
canal
parenteral administration
new formulation
acid
Prior art date
Application number
PE2003000511A
Other languages
English (en)
Inventor
Jean Marie Stassen
Bernd Kruss
Annerose Mauz
Karin Ruehr
Claus Veit
Klaus Wagner
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040066A1 publication Critical patent/PE20040066A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

QUE COMPRENDE: A)UN COMPLEJO DE BIII 890 O DE UNA DE SUS SALES FARMACOLOGICAMENTE ACEPTABLES; Y, B)CICLODEXTRINA SELECCIONADA DE Ò-CD, HP-Ò-CD, HP-ß-CD, Y SBE-ß-CD. DONDE LA SUSTANCIA ACTIVA ES EL HIDROCLORURO DE BIII 890, QUE TIENE UNA CONCENTRACION DE 0,3 mg/ml A 15 mg/ml Y LA RELACION MOLAR SUSTANCIA ACTIVA-CICLODEXTRINA SE ENCUENTRA ENTRE 1:1 Y 1:5 . DICHA COMPOSICION SE APLICA VIA PARENTERAL O VIA INTRAVENOSA PARA EL TRATAMIENTO DE ACCIDENTE CEREBROVASCULAR. ASIMISMO, DICHA COMPOSICION PUEDE TAMBIEN CONTENER UN HIDROXIACIDO SELECCIONADO DE ACIDO MALICO, ACIDO LACTICO, ACIDO TARTARICO Y ACIDO CITRICO
PE2003000511A 2002-05-29 2003-05-27 NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na PE20040066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
PE20040066A1 true PE20040066A1 (es) 2004-03-22

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000511A PE20040066A1 (es) 2002-05-29 2003-05-27 NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na

Country Status (12)

Country Link
EP (1) EP1511517B1 (es)
JP (1) JP2005527615A (es)
AR (1) AR040134A1 (es)
AT (1) ATE373492T1 (es)
AU (1) AU2003237664A1 (es)
CA (1) CA2487150A1 (es)
DE (2) DE10223783A1 (es)
ES (1) ES2294295T3 (es)
PE (1) PE20040066A1 (es)
TW (1) TW200400029A (es)
UY (1) UY27823A1 (es)
WO (1) WO2003099336A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2415131A1 (en) * 2000-07-24 2002-01-31 Boehringer Ingelheim Pharmaceuticals, Inc. Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
DE10223783A1 (de) 2003-12-11
UY27823A1 (es) 2003-12-31
ATE373492T1 (de) 2007-10-15
JP2005527615A (ja) 2005-09-15
TW200400029A (en) 2004-01-01
EP1511517A1 (de) 2005-03-09
DE50308227D1 (de) 2007-10-31
AR040134A1 (es) 2005-03-16
ES2294295T3 (es) 2008-04-01
AU2003237664A1 (en) 2003-12-12
CA2487150A1 (en) 2003-12-04
WO2003099336A1 (de) 2003-12-04
EP1511517B1 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
PT1299107E (pt) Solucoes estaveis muito concentradas de meloxicam
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
NO20064808L (no) Orale matrixformuleringer med licarbazepin
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
PE20040066A1 (es) NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
UY26211A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
SV2001000093A (es) Formas polimorfas de un citrato de azobiciclo 2,2,2, octan-3-amina y sus composiciones farmaceuticas ref.pcl0216/82962/bb
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
CR6513A (es) Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas
PE20040067A1 (es) Nueva formulacion para la administracion parenteral de crobenetina
AR012187A1 (es) Composicion farmaceutica libre de lactosa que contiene noratemizol como agente activo, formas de dosificacion que contiene dicha composicion y metodopara el tratamiento de desordenes alergicos con aplicacion de dicha composicion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal